MK-677 Ibutamoren UK 2026 Research Reference

For laboratory research use only. This page summarises published scientific literature on MK-677 Ibutamoren in plain English, in a neutral research style. It is not medical advice and contains no guidance on doses, administration or human use.

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 3. Receptor pharmacology: GHSR-1a oral agonist
• 4. Pharmacokinetics and oral bioavailability
• 6. Tonic vs pulsatile somatotroph stimulation
• 7. Bone and muscle endpoints — the long-term trials
• 8. Elderly and sarcopenia research
• 9. Hip fracture research applications trials
• 10. Obesity and body-composition effects
• 11. HPA axis effects — cortisol, prolactin
• 12. Insulin sensitivity and glucose handling
• References

3. Receptor pharmacology: GHSR-1a oral agonist

MK-677 is a selective agonist at GHSR-1a (the ghrelin receptor), with EC50 in the low nanomolar range in in vitro receptor assays. Key pharmacological properties:

• Full agonist at GHSR-1a (no partial agonism)
• Minimal activity at closely related receptors (motilin, neuromedin U)
• No significant activity at GHRH receptor, somatostatin receptors, or classical monoamine receptors

Mechanism of GH release: same as other ghrelin-receptor agonists — Gαq → PLC → IP₃/DAG → Ca²⁺ and PKC, producing somatotroph GH vesicle exocytosis. Also suppresses periventricular somatostatin release via hypothalamic GHSR-1a activation, lifting the tonic brake on GH release.

4. Pharmacokinetics and oral bioavailability

• Plasma half-life: 4-6 hours
• Food effect: modest; high-fat meal delays Tmax by ~1 hour and reduces Cmax ~20% but does not affect total AUC
• Primary metabolism: hepatic, CYP3A4

6. Tonic vs pulsatile somatotroph stimulation

MK-677 produces sustained, predominantly tonic activation of GHSR-1a. Consequences:

• 24-hour GH AUC increases substantially (~60-100%)
• Individual GH pulse amplitude increases modestly
• Pulse frequency may actually increase in some cohorts
• Trough GH concentrations between pulses are elevated compared to placebo

7. Bone and muscle endpoints — the long-term trials

MK-677 is distinguished from most secretagogues by having substantial long-term (12-24 month) trial data.

8. Elderly and sarcopenia research

The rationale for MK-677 in sarcopenia research is that age-related GH/IGF-1 decline (somatopause) contributes to muscle loss and that restoring younger IGF-1 levels may slow or reverse the decline. Key trial data:

• Fat mass: −0.5 to −1 kg
• Strength (grip, leg press): modest improvements, study-dependent
• Functional outcomes (stair climbing, 6-minute walk): statistically significant improvements in some but not all cohorts

The magnitude of effect is modest compared to resistance exercise, but additive to exercise in combination designs.

9. Hip fracture research applications trials

The rehabilitation context is a research niche of continuing interest because IGF-1 restoration has mechanistic rationale for muscle re-accretion after prolonged immobilisation.

10. Obesity and body-composition effects

MK-677 effects on body composition include:

• Fat mass change: modest decrease (0.5-1 kg) despite increased appetite
• Waist circumference: modest reduction

11. HPA axis effects — cortisol, prolactin

MK-677 selectivity at GHSR-1a gives it a clean HPA profile:

• Prolactin: no meaningful elevation
• ACTH: no significant change

12. Insulin sensitivity and glucose handling

Chronic MK-677 produces modest insulin resistance, mediated by the known counter-regulatory effect of elevated GH/IGF-1 on insulin signalling:

• Fasting insulin: +20-40%
• HOMA-IR: typically increased by ~30%
• HbA1c: typically increased by 0.1-0.3% (generally not clinically relevant in non-diabetic cohorts)

Limits of the evidence

Published findings come from specific study designs, often in cell systems or animals, and do not transfer automatically to other settings. A paper about a molecule is not proof that any particular batch has a given biological effect. Purity data show what is in a vial; they do not show sterility, safety or suitability for any use outside the laboratory.

Laboratory handling

• Store lyophilised powder sealed, cold (−20 °C for long-term storage), dry and protected from light.
• Let vials reach room temperature before opening to limit condensation.
• Prepare solutions with suitable laboratory solvents and calibrated equipment, and label each with lot number, concentration and date.
• Split solutions into single-use aliquots and avoid repeated freeze–thaw cycles.
• Use the peptide calculator for concentration arithmetic (mg/mL).

References

1. Patchett AA et al. Design and biological activities of L-163,191 (MK-677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA 1995;92:7001–7005.
2. Chapman IM et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/IGF-1 axis in selected GH-deficient adults. J Clin Endocrinol Metab 1997;82:4249–4257.
3. Murphy MG et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998;83:320–325.
4. Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults (2-year MK-677 trial). Ann Intern Med 2008;149:601–611.
5. Svensson J et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998;83:362–369.
6. Adunsky A et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture. Arch Gerontol Geriatr 2011;53:183–189.
7. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45–53.
8. Cordoba-Chacon J et al. Somatotrope-specific deletion of the ghrelin receptor. Mol Endocrinol 2013;27:1731–1745.
9. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005;85:495–522.
10. Müller TD, Nogueiras R et al. Ghrelin. Mol Metab 2015;4:437–460.

UK Research Cluster Hubs

• GLP-1 Research Hub
• Tirzepatide Hub
• Retatrutide Hub
• BPC-157 Research Hub
• TB-500 Research Hub
• Growth-Hormone Peptides Hub
• Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.

For laboratory research use only. MK-677 Ibutamoren sold by Peptides Lab UK is supplied strictly for in vitro laboratory research. It is not for human or veterinary use, and nothing on this page is medical advice or guidance on administration. UK purchasers are responsible for complying with all applicable legislation.